CARM (CARISMA Therapeutics) EV-to-EBIT : -0.18 (As of Dec. 03, 2024)

CARISMA Therapeutics EV-to-EBIT Chart

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial									-0.95	-0.50	-0.53	-0.41	-0.26

Competitive Comparison of CARISMA Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, CARISMA Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's EV-to-EBIT falls into.

CARISMA Therapeutics EV-to-EBIT Calculation

CARISMA Therapeutics's EV-to-EBIT for today is calculated as:

CARISMA Therapeutics's current Enterprise Value is $11.91 Mil.
CARISMA Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics  (NAS:CARM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

CARISMA Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

CARISMA Therapeutics's Enterprise Value for the quarter that ended in Sep. 2024 was $17.42 Mil.
CARISMA Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-66.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics Business Description